Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 2000; 41: 1276–1283., ; for the European Levetiracetam Study Group.
Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 1751–1760., , , , ; Levetiracetam N01057 Study Group.
Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402–408., , , , ; Levetiracetam Monotherapy Study Group.
Levetiracetam reduces spike-wave density and duration during continuous EEG monitoring in patients with idiopathic generalized epilepsy. Epilepsia 2004; 45: 90–91., , , , , , , .
Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Reviews in Neurotherapeutics 2010; 10: 119–140., .
Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611–1613., , , .
Anti-epileptic drug interactions. A clinical guide. Clarius Press: Guildford, UK; 2005..
Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacology and Therapeutics 2000; 85: 77–85..
Clinical pharmacokinetics of levetiracetam. Clinical Pharmacokinetics 2004; 43: 707–724..
Levetiracetam: pharmacology and therapeutics in the treatment of epilepsy and other neurological conditions. Reviews in Contemporary Pharmacotherapy 2004; 13: 1–168..
In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 2006; 47: 1818–1821., , , .
Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574–1579., , , , , , .
Levetiracetam reduces frequency and duration of epileptic activity in patients with refractory primary generalized epilepsy. Seizure 2006; 15: 428–433., , .
Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179–1186., , , , ; for the European Levetiracetam Study Group.
Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Research 2006; 71: 32–39., , , , , , .